Theriva Biologics Inc
F:SFY
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.1616
14
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SFY stock under the Base Case scenario is 0.94 EUR. Compared to the current market price of 2.42 EUR, Theriva Biologics Inc is Overvalued by 61%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Theriva Biologics Inc
Run backtest to discover the historical profit from buying and selling SFY based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Theriva Biologics Inc
Balance Sheet Decomposition
Theriva Biologics Inc
Current Assets | 21.7m |
Cash & Short-Term Investments | 18.3m |
Receivables | 1.9m |
Other Current Assets | 1.5m |
Non-Current Assets | 27.1m |
PP&E | 21.3m |
Intangibles | 5.6m |
Other Non-Current Assets | 176k |
Current Liabilities | 6m |
Accounts Payable | 571k |
Accrued Liabilities | 4.5m |
Other Current Liabilities | 948k |
Non-Current Liabilities | 8.6m |
Long-Term Debt | 159k |
Other Non-Current Liabilities | 8.4m |
Earnings Waterfall
Theriva Biologics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-21.6m
USD
|
Operating Income
|
-21.6m
USD
|
Other Expenses
|
2.6m
USD
|
Net Income
|
-19m
USD
|
Free Cash Flow Analysis
Theriva Biologics Inc
USD | |
Free Cash Flow | USD |
SFY Profitability Score
Profitability Due Diligence
Theriva Biologics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Theriva Biologics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
SFY Solvency Score
Solvency Due Diligence
Theriva Biologics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Theriva Biologics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SFY Price Targets Summary
Theriva Biologics Inc
According to Wall Street analysts, the average 1-year price target for SFY is 2.74 EUR with a low forecast of 0.68 EUR and a high forecast of 4.94 EUR.
Shareholder Yield
Current shareholder yield for SFY is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
SFY Price
Theriva Biologics Inc
Average Annual Return | -36.48% |
Standard Deviation of Annual Returns | 31.78% |
Max Drawdown | -100% |
Market Capitalization | 41.5m EUR |
Shares Outstanding | 17 277 400 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 21 full-time employees. The firm is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patients immune system. The Company’s lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one SFY stock under the Base Case scenario is 0.94 EUR.
Compared to the current market price of 2.42 EUR, Theriva Biologics Inc is Overvalued by 61%.